Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration

AstraZeneca400 enrolled

Overview

A multicentre observational study on treatment patterns and ctDNA HRR evaluation in aggressive high-volume metastatic hormone-sensitive prostate cancer in Russian Federation

This is a multicentre observational study on treatment approaches, demographic and clinical characteristics and on HRRm evaluation in ctDNA in patients with high-aggressive high-volume mHSPC with known tumor HRRm status in Russian Federation. The study will sequentially include only those patients who have signed the informed consent form (ICF). No procedures will be applied to patients in addition to the routine clinical practice. Study population will consist of patients with high-aggressive (Gleason 8-10) high-volume mHSPC with available medical history and known tumor HRRm status, which has been determined from a tumour sample obtained from the patient as part of routine practice. It is estimated that approximately 400 patients will be enrolled in about 30 sites. In this case, the ratio of patients with HRR gene mutations (HRRm) to patients with wild-type HRR genes (HRRwt) will be approximately 5:3 (250 HRRm and 150 HRRwt), so that both populations are represented in the study sample, including patients without mutations. The study will include two visits carried out according to routine clinical practice. At baseline visit (visit 1) demographic and clinical characteristics and treatment approaches from the date of high-aggressive high-volume mPC diagnosis (date of first metastases verification) till enrollment will be collected based on the patient's medical records. In case of absence of data required to be collected by the protocol, additional data may be obtained during patient's interview directly and recorded in the source documents related to the visit. For ctDNA and ctDNA-based HRRm testing (by NGS) routinely collected blood samples will be used. Testing will be performed in central laboratories. Visit 2 (final visit) will be conducted at the time of disease progression or after 12 (±3) months (whichever occurs first) to collect follow-up data on progression to mCRPC and subsequent treatment, if applicable. If the patient is unable to visit the study site (e.g. in case the patient is being treated and observed at the place of residence) the data collection of visits 2 could be carried out via telephone contact. All study data will be entered into electronic case report form (eCRF). The study physician will be responsible for ensuring that all required data is collected and entered into the eCRF. Overall expected duration of the study (from the first patient inclusion to the final database lock) is about 38 months, or until 400 eligible patients are included to the study and data on these patients are collected (including follow-up data), whichever occurs first.

Study Type

OBSERVATIONAL

Enrollment

400

Conditions

Prostate Cancer

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male patients aged ≥ 18 years old; 2. Signed ICF, including consent for blood samples ctDNA and ctDNA-based HRRm testing; 3. Metastatic hormone-sensitive prostate cancer (mHSPC) (de novo or progressed from earlier stages); 4. High-aggressive disease (Gleason 8-10); 5. High-volume disease (according to CHAARTED trial criteria: presence of 4 and more (≥4) bone metastases (including at least one (≥1) outside the vertebral column/pelvis) and/or 1 and more (≥1) visceral metastasis); 6. Availability of source medical documentation; 7. Known HRRm status based on tumour sample evaluation performed in routine practice. Exclusion Criteria: 1. Participation in any interventional trial since the mPC diagnosis. 2. Progression to mCRPC.

Locations (26)

Research Site

Arkhangelsk, Russia

RECRUITING

Outcomes

Primary Outcomes

Proportion of patients received any ADT

Proportion of patients received any Androgen deprivation therapy

Time frame: 36 months

Proportion of patients received ADT by each type and by each drug

Proportion of patients received Androgen deprivation therapy by each type and by each drug

Time frame: 36 months

Proportion of patients received first generation antiandrogens

Time frame: 36 months

Proportion of patients received androgen receptor pathway inhibitors (ARPI) at mHSPC

Proportion of patients received androgen receptor pathway inhibitors (ARPI) at mHSPC overall and by each drug;

Time frame: 36 months

Duration of ARPI therapy

Duration (months) of androgen receptor pathway inhibitors (ARPI) therapy

Time frame: 36 months

Proportion of patients received any chemotherapy at mHSPC

Proportion of patients received any chemotherapy at metastatic hormone-sensitive prostate cancer

Time frame: 36 months

Duration of chemotherapy

Duration (months) of chemotherapy, No. of cycles of chemotherapy;

Time frame: 36 months

Proportion of patients received radiation therapy

Proportion of patients received radiation therapy (RT) overall and by each type (if applicable);

Time frame: 36 months

Central Contacts

AstraZeneca Clinical Study Information Center

CONTACT

1-877-240-9479 information.center@astrazeneca.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Age at the diagnosis of high-aggressive high-volume mPC

Age at the diagnosis of high-aggressive high-volume Metastatic prostate cancer (mPC)

Time frame: 36 months

Proportion of patients of different races and ethnicities

Proportion of patients of different races and ethnicities overall and in subgroups HRRm/HRRwt;

Time frame: 36 months

Proportion of patients with presence of a family oncology history

Proportion of patients with presence of a family oncology history (first degree relatives) overall and by each disease, in the total sample and in subgroups HRRm/HRRwt;

Time frame: 36 months

Proportion of patients with a personal oncology history

Proportion of patients with a personal oncology history overall and by each disease, in the total sample and in subgroups HRRm/HRRwt;

Time frame: 36 months

Proportion of patients with each category by ECOG assessmen

Proportion of patients with each category by Eastern Cooperative Oncology Group (ECOG) assessment at the inclusion;

Time frame: 36 months

Proportion of patients with each type of mPC diagnosi

Proportion of patients with each type of Metastatic prostate cancer (mPC) diagnosis (de novo, metachronous);

Time frame: 36 months

Proportion of patients with each stage by TNM classification

Proportion of patients with each stage by TNM classification;

Time frame: 36 months

Proportion of patients with each histological type of tumor

Proportion of patients with each histological type of tumor (types of adenocarcinoma);

Time frame: 36 months

Proportion of patients with each category by Gleason scale

Proportion of patients with each category (8 (4+4), 8 (3+5), 8 (5+3), 9, 10)) by Gleason scale, in the total sample and in subgroups (de novo and in metachronous mPC, HRRm/HRRwt, ctDNA+/ctDNA-);

Time frame: 36 months

Time from initial diagnosis to mPC diagnosis

Time from initial diagnosis to mPC diagnosis (calculated for patients with metachronous disease, as a time period between the date of initial diagnosis of PC and the date of confirmed metastatic disease diagnosis);

Time frame: 36 months

Proportion of patients with each localization of metastases at the diagnosis of mPC

Proportion of patients with each localization of metastases at the diagnosis of mPC (confirmed metastatic disease), symptomatic or not;

Time frame: 36 months

PSA level at the diagnosis of mPC

PSA level at the diagnosis of mPC (confirmed metastatic disease);

Time frame: 36 months

Proportion of patients with each HRR mutation among all HRRm patient

Proportion of patients with each HRR mutation among all HRRm patients, in the total sample and in subgroups (de novo and in metachronous mPC, ctDNA+/ctDNA-);

Time frame: 36 months

Proportion of patients with each source of tumor sample

Proportion of patients with each source of tumor sample (primary tumor, metastases), which was used for the HRRm status determination in routine practice;

Time frame: 36 months

Proportion of patients with presence of ctDNA

Proportion of patients with presence of ctDNA, in the total sample and in subgroups (de novo and in metachronous mPC, HRRm/HRRwt);

Time frame: 36 months

ctDNA HRRm/HRRwt and tumor HRRm/HRRwt coincidence rate

ctDNA HRRm/HRRwt and tumor HRRm/HRRwt coincidence rate.

Time frame: 36 months